Conversation in Interventional Cardiology: Drug-Coated Balloons for De Novo Non–aorto-ostial and Coronary Bifurcation Lesions: A Systematic Review and Meta-analysis
How to Register
  1. To register, press the "Login" or "Get Started" button.
  2. Sign in with your scai.org username and password. If you don't have an account, click “Set Up Your Login.”
Overview
This conversation focuses on equipping interventional cardiologists with evidence-based strategies for the use of drug-coated balloons in complex coronary lesions, addressing key gaps in knowledge, procedural technique, and patient care to improve outcomes in de novo bifurcation and ostial disease.

Read the article in JSCAI here.
Faculty

 

Andrew M. Goldsweig, MD, FSCAI 
Moderator
  Enrique Soltero Mariscal, MD Presenting Author
Atul Sharma, MD
Panelist
Ron Waksman, MD, MSCAI
Panelist

 

Acknowledgment of Commercial Support
This activity is supported by an unrestricted educational grant from Boston Scientific.
Learning Objectives
Upon completion of this activity, participants will be able to:
  • Evaluate the clinical evidence supporting DCB use in de novo CBL and NAO lesions
  • Demonstrate the procedural steps for optimal lesion preparation prior to DCB angioplasty
  • Identify patient and lesion characteristics that predict favorable outcomes with DCB
  • Design a follow-up plan to monitor for TLF and manage complications after DCB-based PCI
Disclosures
Individuals in control of content reported the following relevant financial relationships with ineligible companiesduring the content development process for this activity. All relevant financial relationships were mitigated beforethe start of the activity. ​  

Planner

Alexandra Lansky: Boston Scientific - speaker; Cordis - consulting; Microport - speaker.

Faculty

Andrew Goldsweig, Enrique Soltero Mariscal, and Atul Sharma: No financial relationships with ineligible companies.
Christian Spaulding: Amgen - speaker: Cordis - Advisory Board; MedAlliance - stock options; Novartis - speaker.
Ron Waksman: Abbott Vascular – Advisory Board, consulting, honorarium,; Cordis – consulting; Philips – Advisory Board, honorarium. 

Reviewer

Nathaniel Hall: No financial relationships with ineligible companies.

SCAI Staff


Kristen Perry and Amanda Pettyjohn:
No financial relationships with ineligible companies.
Continuing Education Information

Accreditation Statement
The Society for Cardiovascular Angiography & Interventions (SCAI) is accredited by the
Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

​Credit Designation
SCAI designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

​ABIM MOC
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Successful Completion
Watch the content and complete the evaluation to obtain credit.

Activity Timeline
Recoding date: 2/11/2026
Publish date: 5/12/2026
Expiration date: 5/12/2029

SCAI's Independent Content

As a provider of continuing medical education through the Accreditation Council for Continuing Medical Education (ACCME), it is the Society’s policy to ensure balance, independence, objectivity, and scientific rigor in all its activities.

Planning Process 
SCAI activities are developed by the SCAI planners prior to and independent of commercial support. This activity was developed by the Journal Editor-in-Chief and reviewed and approved by the Editorial Board. If planners had relevant financial relationships, the agenda was peer reviewed by a member with no relevant financial relationships.

Mitigation of Relevant Financial Relationships
All participating planners, reviewers, faculty, and staff are required to disclose to SCAI all financial relationships with ineligible companies. SCAI identifies relevant financial relationships and mitigates them before the activity begins. 

Content Validation Statement
SCAI accepts the following Content Validation Statements and expects all persons involved in its professional education activities to abide by these statements for clinical care recommendations.

All clinical and pharmacological recommendations are based on evidence accepted within the medical profession as adequate jurisdiction for their indications and contradictions in patient care. SCAI does not promote recommendations, treatment, or manners of practicing medicine that are not within the definition of accredited continuing education or known to have risks or dangers that outweigh the benefits or known to be ineffective in the treatment of patients.

All research referenced to support or justify patient care recommendations conforms to accepted standards of experimental design, data collection and analysis. 

SCAI actively promotes improvements in health care and NOT proprietary interests of an ineligible company. SCAI's educational content is free of marketing or sales of products or services.

Faculty will not actively promote or sell products or services that serve their professional or financial interests during accredited education. 

SCAI encourages faculty to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration (FDA), at first mention and where appropriate in the content.

Copyright
© 2026 Society for Cardiovascular Angiography and Interventions (SCAI). All rights reserved.
Summary
Availability:
On-Demand
Access expires on May 12, 2029
Cost:
FREE
Credit Offered:
0.25 CME Credit
0.25 ABIM-MOC Point
0.25 Participation Credit
Powered By